cGAS-STING, an important pathway in cancer immunotherapy.
Adenylyl Cyclases
/ physiology
Adjuvants, Immunologic
Animals
CTLA-4 Antigen
/ antagonists & inhibitors
Cancer Vaccines
/ immunology
Clinical Trials as Topic
DNA
/ metabolism
DNA, Neoplasm
/ metabolism
Drug Screening Assays, Antitumor
Humans
Immune Checkpoint Inhibitors
/ therapeutic use
Immunotherapy
Immunotherapy, Adoptive
Membrane Proteins
/ agonists
Mice
Neoplasm Proteins
/ agonists
Neoplasms
/ immunology
Nucleotides, Cyclic
/ physiology
Oncolytic Virotherapy
Protein Multimerization
Signal Transduction
/ drug effects
Therapies, Investigational
Cancer
Combined therapy
Immunotherapy
STING pathway
cGAS-STING
Journal
Journal of hematology & oncology
ISSN: 1756-8722
Titre abrégé: J Hematol Oncol
Pays: England
ID NLM: 101468937
Informations de publication
Date de publication:
22 06 2020
22 06 2020
Historique:
received:
30
03
2020
accepted:
11
06
2020
entrez:
24
6
2020
pubmed:
24
6
2020
medline:
18
5
2021
Statut:
epublish
Résumé
Cytosolic DNA sensing, the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway, is an important novel role in the immune system. Multiple STING agonists were developed for cancer therapy study with great results achieved in pre-clinical work. Recent progress in the mechanical understanding of STING pathway in IFN production and T cell priming, indicates its promising role for cancer immunotherapy. STING agonists co-administrated with other cancer immunotherapies, including cancer vaccines, immune checkpoint inhibitors such as anti-programmed death 1 and cytotoxic T lymphocyte-associated antigen 4 antibodies, and adoptive T cell transfer therapies, would hold a promise of treating medium and advanced cancers. Despite the applications of STING agonists in cancer immunotherapy, lots of obstacles remain for further study. In this review, we mainly examine the biological characters, current applications, challenges, and future directions of cGAS-STING in cancer immunotherapy.
Identifiants
pubmed: 32571374
doi: 10.1186/s13045-020-00916-z
pii: 10.1186/s13045-020-00916-z
pmc: PMC7310007
doi:
Substances chimiques
Adjuvants, Immunologic
0
CTLA-4 Antigen
0
CTLA4 protein, human
0
Cancer Vaccines
0
DNA, Neoplasm
0
Immune Checkpoint Inhibitors
0
Membrane Proteins
0
Neoplasm Proteins
0
Nucleotides, Cyclic
0
STING1 protein, human
0
cyclic guanosine monophosphate-adenosine monophosphate
0
DNA
9007-49-2
Adenylyl Cyclases
EC 4.6.1.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
81Références
Mol Cancer Res. 2019 Apr;17(4):974-986
pubmed: 30587523
Blood. 2001 Nov 15;98(10):3022-9
pubmed: 11698286
Cell Rep. 2014 Oct 9;9(1):75-89
pubmed: 25263564
Cancer Res. 2009 Apr 1;69(7):3077-85
pubmed: 19293190
Nature. 2018 Dec;564(7736):439-443
pubmed: 30405246
Biochem Biophys Res Commun. 2005 Apr 1;329(1):40-5
pubmed: 15721270
Nature. 2018 Jan 25;553(7689):467-472
pubmed: 29342134
Nature. 2016 May 18;533(7604):493-498
pubmed: 27225120
Nature. 2008 Oct 2;455(7213):674-8
pubmed: 18724357
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Sci Transl Med. 2015 Apr 15;7(283):283ra52
pubmed: 25877890
Trends Immunol. 2016 Mar;37(3):193-207
pubmed: 26839260
J Immunol. 2016 Apr 1;196(7):3191-8
pubmed: 26927800
Cell Rep. 2015 May 19;11(7):1018-30
pubmed: 25959818
J Clin Oncol. 2011 Aug 1;29(22):2965-71
pubmed: 21709202
J Clin Oncol. 2015 Sep 1;33(25):2780-8
pubmed: 26014293
Nature. 2015 Apr 23;520(7548):553-7
pubmed: 25642965
Lung Cancer. 2009 Aug;65(2):192-7
pubmed: 19409645
Cancer Cell. 2014 Jan 13;25(1):37-48
pubmed: 24434209
Immunity. 2018 Oct 16;49(4):754-763.e4
pubmed: 30332631
Immunol Rev. 2019 Jul;290(1):24-38
pubmed: 31355488
JCI Insight. 2018 Oct 18;3(20):
pubmed: 30333318
Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4612-E4620
pubmed: 28533362
Nat Commun. 2016 Jun 21;7:11932
pubmed: 27324217
Mol Cancer. 2018 Jan 12;17(1):7
pubmed: 29329591
Nat Immunol. 2019 Feb;20(2):152-162
pubmed: 30643259
Nature. 2013 Jun 20;498(7454):332-7
pubmed: 23722159
J Exp Med. 2011 Sep 26;208(10):1989-2003
pubmed: 21930769
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Cancer Res. 2016 Apr 15;76(8):2137-52
pubmed: 26951929
Cancer Res. 2016 Apr 15;76(8):2076-81
pubmed: 26964621
Nature. 2013 Jun 20;498(7454):380-4
pubmed: 23722158
Cancer Immunol Immunother. 2015 Aug;64(8):1057-66
pubmed: 25986168
Cell Rep. 2013 May 30;3(5):1355-61
pubmed: 23707065
J Exp Med. 2011 Sep 26;208(10):2005-16
pubmed: 21930765
Cell Rep. 2018 Dec 11;25(11):3074-3085.e5
pubmed: 30540940
Nanomedicine. 2018 Feb;14(2):237-246
pubmed: 29127039
PLoS Biol. 2008 Dec 2;6(12):2853-68
pubmed: 19053174
Cell. 2013 Aug 15;154(4):748-62
pubmed: 23910378
Nat Rev Immunol. 2015 Dec;15(12):760-70
pubmed: 26603901
Nature. 2017 Aug 24;548(7668):466-470
pubmed: 28759889
Nat Rev Cancer. 2018 Aug;18(8):526
pubmed: 29728690
J Immunother Cancer. 2019 Feb 13;7(1):46
pubmed: 30760319
Cancer Discov. 2020 Jan;10(1):26-39
pubmed: 31852718
Ann Oncol. 2014 Feb;25(2):358-65
pubmed: 24299959
Nature. 2018 Oct;562(7727):423-428
pubmed: 30305738
Biochim Biophys Acta. 2015 Nov;1852(11):2494-503
pubmed: 26303640
Nat Immunol. 2013 Jan;14(1):19-26
pubmed: 23238760
Annu Rev Med. 2017 Jan 14;68:139-152
pubmed: 27860544
Trends Immunol. 2013 Feb;34(2):67-73
pubmed: 23122052
Br J Cancer. 2018 Jan;118(1):9-16
pubmed: 29319049
Cancer Res. 2018 Feb 15;78(4):1044-1057
pubmed: 29259014
Immunity. 2014 Nov 20;41(5):830-42
pubmed: 25517615
Cancer Res. 2016 Nov 15;76(22):6747-6759
pubmed: 27680683
J Immunol. 2013 May 15;190(10):5216-25
pubmed: 23585680
Cancer Immunol Res. 2017 Aug;5(8):676-684
pubmed: 28674082
Nat Cell Biol. 2017 Sep;19(9):1061-1070
pubmed: 28759028
J Hematol Oncol. 2017 May 8;10(1):103
pubmed: 28482851
Science. 2013 Feb 15;339(6121):786-91
pubmed: 23258413
Sci Rep. 2017 Feb 08;7:39858
pubmed: 28176788
Oncogene. 2019 Mar;38(13):2380-2393
pubmed: 30518877
Nat Immunol. 2016 Sep 20;17(10):1142-9
pubmed: 27648547
Nat Commun. 2017 Sep 5;8(1):427
pubmed: 28874664
Sci Rep. 2016 Jan 12;6:19049
pubmed: 26754564
Mol Cancer. 2018 May 16;17(1):91
pubmed: 29769134
Nat Nanotechnol. 2019 Mar;14(3):269-278
pubmed: 30664751
Nature. 2018 Nov;563(7729):131-136
pubmed: 30356214
Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15408-13
pubmed: 26607445
Semin Immunol. 2010 Jun;22(3):155-61
pubmed: 20488726
Curr Opin Immunol. 2018 Feb;50:82-87
pubmed: 29247853
J Clin Invest. 2017 Jun 1;127(6):2176-2191
pubmed: 28436934
Science. 2018 Jun 15;360(6394):
pubmed: 29773669
Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720-4
pubmed: 8421711
Nature. 2019 Mar;567(7748):389-393
pubmed: 30842659
Cancer Res. 2019 Apr 1;79(7):1465-1479
pubmed: 30482772
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nature. 2018 Jul;559(7713):269-273
pubmed: 29973723
Cell Rep. 2016 Jan 12;14(2):282-97
pubmed: 26748708
Nature. 2019 Mar;567(7748):394-398
pubmed: 30842653
Cancer Discov. 2019 Jan;9(1):34-45
pubmed: 30297358
Mol Ther Nucleic Acids. 2019 Mar 1;14:80-89
pubmed: 30583098
Trends Mol Med. 2019 May;25(5):412-427
pubmed: 30885429
J Hematol Oncol. 2019 Apr 1;12(1):35
pubmed: 30935414
Nature. 2017 Oct 19;550(7676):402-406
pubmed: 28976970
Clin Cancer Res. 2018 Sep 1;24(17):4242-4255
pubmed: 29769207
Nat Biotechnol. 2019 Oct;37(10):1174-1185
pubmed: 31570898